保密 | 投资责任声明 | 联系我们
Excorp Medical's Bioartificial Liver System comprises a reusable instrument, disposable tubing set and the proprietary, disposable bioartificail reactor.Once approved by regulatory agencies, Excorp Medical expects this breakthrough Bioartificial Liver System technology to be both live-saving and cost effective.Certain drugs or machines are available to substitute temporarily or long-term for many organs in the body…  no comparable substitute has been developed for the liver.The liver is the largest organ in the body and performs a variety of tasks impacting all body systems… as a result liver disease has widespread effects on virtually all other organs.Excorp Medical is currently the only company approved to conduct bioartificial liver human trials within the U.S.Currently patients must receive a liver transplant or endure prolonged hospitalization at great expense to have a chance at survival.Excorp Medical Bioartificial Liver System treatments serve as a bridge to liver regeneration and transplantExcorp Medical has developed a Bioartificial Liver System for the metabolic support of patients with compromised liver function.
Chinese Simplified
简体中文
Chinese Traditional
繁體中文
Arabic

公司介绍


爱克思科医疗设备有限公司成立于1995年11月22日,是一家总部位于美国,并在美国明尼苏达州注册成立的公司 公司拥有一家座落于中国江苏省无锡市的外商独资控股公司,和一家位于香港的外商独资子公司 公司还计划在山东省淄博市成立一家合资公司,即新华爱克思科生物科学有限公司,并拟于湖南省娄底市成立一间制造基地,即娄底埃斯科普制造有限公司

爱克思科医疗设备有限公司及其子公司的近期目标是:在急症肝功能衰竭患者肝脏自我修复,或者肝脏移植手术成功之前, 为之提供有效,且性价比极高的临时肝功能支持

公司的长期目标是加速向全球推广人工生物肝脏系统这一能够挽救生命,且性价比极高的技术


主页 | 介绍 | 人工生物肝脏系统 | 公司介绍 | 管理团队
新闻 | 关联单位 | 出版文章 | 临床研究 | 股东专栏 | 招聘 | 致投资者
保密 | 投资责任声明 | 联系我们


新闻
关联单位
出版文章
临床研究
招聘
致投资者
©2014 Excorp Medical, Inc.